Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): similarities and differences.

Literature DB >> 25696573

Angiotensin II receptor antagonists (AT₁-blockers, ARBs, sartans): similarities and differences.

Abstract

A survey is presented of the registered non-peptidergic angiotensin II receptor antagonists (AT1 blockers, ARBs, sartans) and their general properties and similarities. Accordingly, their receptor profile, pharmacokinetic and therapeutic applications are discussed. In addition, attention is paid to the individual characteristics of the AT1 blockers now available. A few components of this category offer additional potentially beneficial properties, owing to their pharmacological or metabolic characteristics. Such additional properties are critically discussed for eprosartan, losartan, telmisartan and valsartan.

Entities: Chemical Gene

Keywords: AT1 receptors; angiotensin II receptor antagonists; insulin sensitisation; renin-angiotensin system

Year: 2006 PMID： 25696573 PMCID： PMC2557311

Source DB: PubMed Journal: Neth Heart J ISSN： 1568-5888 Impact factor: 2.380

34 in total

1. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.

Authors: O K Andersson; S Neldam
Journal: Blood Press Date: 1998-01 Impact factor: 2.835

2. Comparative pharmacology of the angiotensin II receptor antagonists.

Authors: D J Dzielak
Journal: Expert Opin Investig Drugs Date: 1998-05 Impact factor: 6.206

3. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors: H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245

Review 4. The angiotensin II receptor and the actions of angiotensin II.

Authors: M J Peach; D E Dostal
Journal: J Cardiovasc Pharmacol Date: 1990 Impact factor: 3.105

5. Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers.

Authors: J Baan; P C Chang; P Vermeij; M Pfaffendorf; P A van Zwieten
Journal: Cardiovasc Res Date: 1996-11 Impact factor: 10.787

6. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Authors: Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen
Journal: N Engl J Med Date: 2004-10-31 Impact factor: 91.245

7. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.

Authors: Giancarlo Viberti; Nigel M Wheeldon
Journal: Circulation Date: 2002-08-06 Impact factor: 29.690

8. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist.

Authors: C Cazaubon; J Gougat; F Bousquet; P Guiraudou; R Gayraud; C Lacour; A Roccon; G Galindo; G Barthelemy; B Gautret
Journal: J Pharmacol Exp Ther Date: 1993-05 Impact factor: 4.030

9. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.

Authors: Michael Schupp; Jürgen Janke; Ronald Clasen; Thomas Unger; Ulrich Kintscher
Journal: Circulation Date: 2004-04-26 Impact factor: 29.690

10. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors: Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal: N Engl J Med Date: 2003-11-10 Impact factor: 91.245

5 in total

4. Investigation of angiotensin-I-converting enzyme (ACE) inhibitory tri-peptides: a combination of 3D-QSAR and molecular docking simulations.

Authors: Fangfang Wang; Bo Zhou
Journal: RSC Adv Date: 2020-09-30 Impact factor: 4.036

5. Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition.

Authors: Nicholas E Thomford; Kevin Dzobo; Denis Chopera; Ambroise Wonkam; Michelle Skelton; Dee Blackhurst; Shadreck Chirikure; Collet Dandara
Journal: Pharmaceuticals (Basel) Date: 2015-09-21